Cardiotoxicity Risk Factors
Certain cancer therapies known to cause cardiovascular complications include:
- Anthracyclines (doxorubicin, daunorubicin, epirubicin)
- HER2 targeted therapies (trastuzumab/Herceptin, pertuzumab/Perjeta)
- Tyrosine Kinase Inhibitors
- VEGF Inhibitors
- Immunotherapies (checkpoint inhibitors)
- Stem Cell Transplantation
- CAR T Therapy
- Radiation to the chest, head or neck
While not every patient who who receives cancer therapy will experience cardiotoxic complications, Moffitt Cancer Center's Cardio-Oncology Program can provide comprehensive risk assessment and monitoring services as a proactive measure. Using technologies such as 3D echocardiograms and mangetic resonance imaging (MRI), we can assess a patient’s cardiovascular function to determine if complications, such as arrhythmias, fibrosis or other issues are beginning to develop and can intervene at an earlier stage. We also offer baseline testing for patients who have an elevated risk due to their biological sex or age, or who are planning to participate in a treatment that could increase their risk of future cardiotoxic complications. Clinical trials are also underway to help identify and evaluate ways to counteract cardiotoxicity risk factors; Moffitt can help you determine if you qualify for any of these studies.
Our all-inclusive clinic treats patients with a wide range of diagnoses, including cancers that are now in remission. For an appointment to discuss your individual risk factors with a member of Moffitt's Cardio-Oncology Program, call 1-888-663-3488 or submit a new patient registration form online; referrals are not required.